Radnet, Inc. (RDNT) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Radnet, Inc. (RDNT) stock forecast summary
On Oct. 16, 2026, RDNT is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Radnet, Inc. is a mid-cap company with a market capitalization of $5.41B. It ranks number 6 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast.
For RDNT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -18.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RDNT included.
Follow RDNT freeRDNT price chart and AI forecast
How RDNT ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Radnet, Inc. (RDNT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | RDNT | Rank |
|---|---|---|
| Market Cap | $5.41B | 6/29 |
| P/B Ratio | 4.94x | 7/22 |
| EPS | $-0.34 | – |
| Book Value/Share | $13.93 | – |
| Revenue/Share | $28.83 | – |
Profitability & Margins
| Metric | RDNT | Rank |
|---|---|---|
| ROE | -1.9% | 5/14 |
| ROA | -0.5% | 5/20 |
| ROIC | 2.0% | 8/24 |
| Operating Margin | 3.1% | 8/23 |
| Net Margin | -0.9% | 6/17 |
| EBT Margin | 1.5% | 7/23 |
| Tax Rate | 44.9% | – |
Financial Health
| Metric | RDNT | Rank |
|---|---|---|
| Current Ratio | 1.48x | 20/26 |
| D/E Ratio | 2.58x | 4/22 |
| Financial Leverage | 3.86x | 4/22 |
| Interest Coverage | 2.2x | 4/23 |
| Working Capital | $338M | 11/26 |
Cash Flow
| Metric | RDNT | Rank |
|---|---|---|
| Operating Cash Flow | $310M | 3/27 |
| OCF Growth YoY | 18.4% | 4/7 |
Operational Efficiency
| Metric | RDNT | Rank |
|---|---|---|
| Asset Turnover | 0.54x | 11/18 |
| Receivables Turnover | 9.4x | 6/19 |
| Fixed Assets Turnover | 2.6x | 14/17 |
| Days Sales Outstanding | 39 days | 14/19 |
Income Statement
| Metric | RDNT | Rank |
|---|---|---|
| Total Revenue | $2.27B | 4/19 |
| Operating Income | $71M | 6/26 |
| Net Income | -$21M | 11/20 |
Dividend & Shareholder Information
| Metric | RDNT | Rank |
|---|---|---|
| Shares Outstanding | 79M | – |
| EPS Growth | -225.9% | 5/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.04B | 24.5% of assets |
| Cash & Short-term Investments | $726M | 17.2% of assets |
| Accounts Receivable | $242M | 5.7% of assets |
| Total Liabilities | $2.83B | 67.0% of assets |
| Short-term Debt | $208M | 4.9% of assets |
RDNT quarterly financials and insider trading
Radnet, Inc. (RDNT) industry peers
Companies classified under the same SEC industry code as Radnet, Inc. (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| RDNT Radnet, Inc. | ▶ | $5.41B |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| LH Labcorp Holdings Inc. | ▶ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▶ | $2.14B |
| PSNL Personalis, Inc. | ▼ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $139M |
| SERA Sera Prognostics, Inc. | ▼ | $80M |
| CFOR Capforce Inc. | ▶ | $43M |
| MDXH Mdxhealth Sa | ▲ | $20M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▶ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▼ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▶ | $260K |
| RNLXY Renalytix Plc | ▲ | N/A |
Where RDNT sits on the market map
Radnet, Inc. (RDNT) stock news
Loading...
Radnet, Inc. (RDNT) stock forecast FAQ
What is the Radnet, Inc. (RDNT) stock forecast?
On Oct. 16, 2026, RDNT is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Radnet, Inc. stock predictions?
For RDNT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -18.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Radnet, Inc. forecasts updated?
Radnet, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Radnet, Inc.'s industry peers?
30 issuers in our coverage, RDNT included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.